All sessions take place 09:00-12:00 Wednesday, 20 June 2018 

google-plus2 facebook < /path> twitter blogger tumblr2 reddit linkedin delicious stumbleupon mail

Using Pluripotent Stem Cells to Treat Diseases of the Nervous System

Organized by BlueRock Therapeutics

In just little over a decade, induced pluripotent stem cells (iPSCs) have changed modern medicine. Based on lessons learned from model systems, hundreds of labs around the world are now using human cells to study human disease and to develop therapies - a truly exiting paradigm shift! Remarkably, scientists, physicians, entrepreneurs and the biopharmaceutical industry were quick to embrace this technology and today iPSCs are being used to understand human pathology, to discover new therapeutic agents or serve as the basis of the therapy itself.

Diseases of the central nervous system (CNS) are of particular interest in a society that becomes older and older and where few disease-modifying therapies exist. In this focus session, we will showcase how pluripotent stem cells are being used to advance our treatment options for CNS disease. Our panel of speakers will conclude in a moderated panel discussion with time for the audience to ask questions.

_MG_0005

Tools for Basic and Applied Research

Organized by Stem Cell COREdinates, Presented by STEMCELL Technologies and Thermo Fisher Scientific

Stem Cell COREdinates is a consortium of human pluripotent stem cell-focused core facilities that have joined forces to share experiences, expertise with protocols and reagents, and to establish “best practices.” Our Focus session will be divided into two parts:

  1. Selected presentations from Stem Cell COREdinates members
  2. Presentations from Internaitonal Stem Cell Organizations: ISCBI, GAiT, hPSCreg, ISCI. 

Setting Ethical Standards: Driving Clinical Translation and Countering Predatory Marketing

Organized by ISSCR Ethics Committee

In this focus session, panelists will discuss ethical and legal issues raised by the continued growth of businesses marketing unproven uses of stem cells, and how academia, medicine, and industry can contribute to the establishment and enforcement of appropriate standards of moral conduct and regulatory policies. We will seek to balance examinations of the illicit industry and the fragmented global regulatory landscape with positive examples of standards-setting work being done by the ISSCR Clinical Translation Committee and successes in stem cell therapeutic development within a regulated framework. Additional focus will be placed on understanding and addressing patients’ perspectives and concerns and the role of medical professionals and medical ethics in confronting misleading claims about stem cells.

Planning, Profiling, and Partnering: Translating a Stem Cell Therapy from the University Lab to the Patient

Organized by ISSCR Industry Committee

With stem cell science rapidly moving from the laboratory towards the patient, there is a growing interest in the translational pathway. This is especially true for academics who are increasingly looking to capitalize on discoveries or those curious about a career in industry. Drawing on experts from industry and academics, this program will highlight key aspects of the process for developing and testing a cell therapy including creating a target product profile, understanding the analytics and standards in addition to building relationships with industry to bring therapies to the clinic.